Novo Nordisk submits obesity drug for FDA approval

Semaglutide will also be used as a treatment for obesity, according to Novo Nordisk's plan – the pharmaceutical giant has submitted an application to the FDA in the US.

Photo: Stine Tidsvilde

Within the next six months, Novo Nordisk will find out whether its drug semaglutide can be used as a treatment for obesity, aside from its use as a drug against diabetes in US patients.

The Danish pharmaceutical giant as used a priority review voucher, which cuts off many months from the estimated review time at the US Food and Drug Administration (FDA). Novo Nordisk bought the voucher from Australian biotech firm Medicines Development for Global Health for an unknown price last year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs